2014 News Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
04/09/14Verastem Presents Data on Cancer Stem Cell-Targeting Agents at the 2014 AACR Annual Meeting
- Research Results Provide Additional Support for Targeting Cancer Stem Cells Directly and Through Immunomodulation of the Tumor Microenvironment – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 9, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the presentation of scientific data at the American Association for Cancer Research annual meetin... 
Printer Friendly Version
03/25/14Verastem to Present Data on Product Candidates Targeting Cancer Stem Cells at the American Association of Cancer Research Meeting
-New research to be presented in an oral session and three poster presentations- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 25, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present data at the upcoming American Association of Cancer Research (AACR) meeting to be held April 5-9, 2014 at the San Diego Convention Center i... 
Printer Friendly Version
03/20/14Verastem to Present at the Boston Business Development Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2014-- Verastem, Inc., (NASDAQ:VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be participating in the upcoming Boston Business Development Conference on Tuesday and Wednesday, March 25-26, 2014. The conference will take place at The Four Seasons Hotel in Boston. About Verastem, Inc.... 
Printer Friendly Version
03/11/14Timothy J. Barberich Joins Verastem Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Timothy J. Barberich to its Board of Directors. “Tim is an entrepreneur at heart who has become a very successful biopharmaceutical business leader,” said Christoph Westphal, M.D., Ph.D., Verastem Executive Chairman. “As ... 
Printer Friendly Version
03/06/14Verastem Reports Year-End 2013 Financial Results
--A year of clinical execution: Three small molecule compounds in clinical development including the registration-directed COMMAND study— --Multiple clinical data readouts anticipated starting in first half 2014-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for t... 
Printer Friendly Version
03/05/14Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients
– Well Tolerated; Meets Study Objectives – – Results Facilitate Potential Parallel Development of VS-6063 (defactinib) in Japan – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2014-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced... 
Printer Friendly Version
03/04/14Verastem to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 4, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at upcoming investor conferences. The presentation details are as follows: 26th Annual Roth Conference on Monday, March 10th at 11:30 a.m. PT at The Ritz Carlton in Dana Point, CA Barclay... 
Printer Friendly Version
02/28/14Verastem Supports Worldwide Rare Disease Day on February 28, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced its support of the rare disease awareness events being held globally. Verastem’s lead compound targeting cancer stem cells, VS-6063, is currently in the registration-directed COMMAND study and has been granted orphan drug designation in the U.S. and E.U. ... 
Printer Friendly Version
02/26/14Verastem to Present at Upcoming Scientific Conferences
-Results from a Phase 1 study of VS-6063 in Japanese patients to be announced- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at two upcoming scientific conferences, including the 12th International Congress on Targeted Anticancer Therapies (TAT), where a poster with... 
Printer Friendly Version
02/25/14Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718
--The acquisition reduces milestones and royalties associated with ongoing VS-4718 development-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals. The previous and future developmental, regulatory and comme... 
Printer Friendly Version
02/24/14Cancer Research Publication Highlights Importance of Merlin Loss and Cancer Stem Cells in Mesothelioma
Research Demonstrates Cooperativity between Loss of Merlin and p16/ARF in Driving the Development of Highly Aggressive Disease In Vivo CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 24, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a publication in the journal Cancer Research supports the scientific rationale for the Company’s ongoing ... 
Printer Friendly Version
02/19/14Verastem to Host Conference Call on March 6th to Discuss Year-End 2013 Financial Results and Recent Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 19, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will host a conference call on Thursday, March 6, 2014 at 8:00 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2013. The call can be accessed by dialing (866) 953-6857 (U.S. and Canad... 
Printer Friendly Version
02/10/14Nature Immunology Paper Highlights Potential Role of FAK Inhibition in Hematological Malignancies
Research from UC Irvine, Massachusetts General Hospital and Tufts Medical Center Points to Potential Development of Verastem FAK inhibitors in subset of Acute Lymphoblastic Leukemia CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a publication in Nature Immunology demonstrates the scien... 
Printer Friendly Version
02/06/14Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at upcoming scientific and investor conferences. The presentation details are as follows: 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 3:00 p.m. ET at the Waldorf Astoria in New ... 
Printer Friendly Version
02/04/14Verastem Issued Japanese Patent on Dual mTORC1/2 and PI3K Inhibitor VS-5584
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has been issued a patent by the Japanese Patent Office (JPO) for the company’s small molecule dual inhibitor of mTORC1/2 and PI3K VS-5584. The granted patent is titled “Pyrimidine Substituted Purine Compounds As Kinase(s) Inhibitors,” and has claim... 
Printer Friendly Version